title: Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.
abstract: Many marketed drugs exhibit high variability in exposure and response. While these drugs are efficacious in their approved indications, finding appropriate dose regimens for individual patients is not straightforward. Similar dose adjustment problems are also seen with drugs that have a complex relationship between exposure and response and/or a narrow therapeutic window. This is particularly true for monoclonal antibodies, where prolonged dosing at a sub-therapeutic dose can also elicit anti-drug antibodies which will further compromise safety and efficacy. Thus, finding appropriate doses quickly would represent a substantial improvement in healthcare. Dashboard systems, which are decision-support tools, offer an improved, convenient means of tailoring treatment for individual patients. This article reviews the clinical need for this approach, particularly with monoclonal antibodies, the design, development, and testing of such systems, and the likely benefits of dashboard systems in clinical practice. We focus on infliximab for reference.
authors.affiliation: Projections Research, Phoenixville, PA, 19460, USA.
authors.forename: Diane R
authors.initials: DR
authors.lastname: Mould
authors.forename: Marla C
authors.initials: MC
authors.lastname: Dubinsky
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D020000:Decision Support Systems, Clinical; D006801:Humans; D000069285:Infliximab; D057285:Precision Medicine
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab
keywords: inflammatory bowel disease; monoclonal antibodies; pharmacodynamics; pharmacokinetics; population modeling